Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Donor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    449 result(s) found for: Blood Donor. Displaying page 1 of 23.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-006146-34 Sponsor Protocol Number: 100505 Start Date*: 2008-04-30
    Sponsor Name:Stage Pharmaceuticals GmbH
    Full Title: Adoptive Immunotherapy of chemotherapy refractory CMV infections using Streptamer-isolated T cells after allogeneic bone marrow or peripheral blood stem cell transplantation: a phase I/II trial
    Medical condition: -chronic persistent CMV infection after allogeneic bone marrow or peripheral blood stem cell transplantation, refractory to antiviral chemotherapy
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004953-26 Sponsor Protocol Number: BHS-TC13 Start Date*: 2016-03-11
    Sponsor Name:Ghent University Hospital
    Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019529-33 Sponsor Protocol Number: 31051970 Start Date*: 2011-11-21
    Sponsor Name:UMCU
    Full Title: A Phase l/ll study to assess safety of co-infusion of haematopoietic stem cells from a haplo-identical donor and a single unit unrelated cord blood in high risk patients
    Medical condition: All patients (0-65y) with a malignancy qualifying for allogenic hematopoietic stem cell transplantation (HSCT) who either (and/or) - are not eligible to other ongoing allo-HSCT protocols, because o...
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000911-25 Sponsor Protocol Number: BST-LT-01 Start Date*: 2019-02-12
    Sponsor Name:Banc de Sang i Teixits
    Full Title: A prospective multicenter open, not controlled phase Ib-II clinical trial to assess the safety and immunologic efficacy of virus-specific T lymphocytes from the best donor in receptors of hematopoi...
    Medical condition: CMV viral infection in an immunocompromised host
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003691-40 Sponsor Protocol Number: LUMC2010-01 Start Date*: 2012-09-19
    Sponsor Name:Leiden University Medical Center
    Full Title: Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood a...
    Medical condition: persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000053-35 Sponsor Protocol Number: 01 Start Date*: 2012-04-11
    Sponsor Name:Erasmus MC
    Full Title: A phase II study to assess engraftment and engraftment kinetics after double cord blood transplantation with a reduced-intensity conditioning regimen in patients eligible for allogeneic stem cell t...
    Medical condition: Patients with high-risk hematological diseases, who need a allogeneic stem cell transplantation but who lack a matched unrelated donor
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004101-26 Sponsor Protocol Number: TJB0601P1 Start Date*: 2006-12-13
    Sponsor Name:CHU Sart-Tilman
    Full Title: Mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning: a pilot study
    Medical condition: Patients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbidities.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027703 Mismatched donor bone marrow transplantation therapy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001522-41 Sponsor Protocol Number: PACT2014-001 Start Date*: 2016-02-08
    Sponsor Name:University Hospital Wuerzburg
    Full Title: Prophylactic application of donor-derived central memory T lymphocytes (TCM) after allogeneic HSCT to prevent infectious complications
    Medical condition: patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after T cell depleted allo-SCT
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028555 Myeloid leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003418-28 Sponsor Protocol Number: CLNA043X2201 Start Date*: 2017-04-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, placebo-controlled, patient and investigator blinded, single dose, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of intra-articular LNA043 in ...
    Medical condition: Acute cartilage injuries
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031161 Osteoarthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002784-25 Sponsor Protocol Number: THO-IM_01-CT Start Date*: 2013-10-04
    Sponsor Name:Thrombotargets Europe
    Full Title: A Phase II, randomized, controlled, double blind study to evaluate the haemostatic efficacy and safety of TT-173 applied in the donor site of patients undergoing skin graft.
    Medical condition: Haemostatic effect in the donor site of patients undergoing skin graft.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10022117 - Injury, poisoning and procedural complications 10022114 Injuries NEC HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-014980-38 Sponsor Protocol Number: TJB0909P1 Start Date*: 2010-07-06
    Sponsor Name:CHU de Liège
    Full Title: Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after reduced-intensity conditioning: a phase II randomized double-blind study.
    Medical condition: Hematological malignancies confirmed histologically and not rapidly progressing: - AML in Complete Remission; - ALL in Complete Remission; - CML unresponsive/intolerant to Imatinib but not in b...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10027703 Mismatched donor bone marrow transplantation therapy PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000985-12 Sponsor Protocol Number: 1719-B Start Date*: 2018-11-26
    Sponsor Name:Leiden University Medical Center
    Full Title: Near-infrared fluorescence imaging in kidney transplantations using ZW800-1 for perfusion assessment: a pilot study
    Medical condition: Patients undergoing a living-donor kidney transplantation (living kidney donor and kidney recipient)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005176-17 Sponsor Protocol Number: BP-I-008 Start Date*: 2016-10-20
    Sponsor Name:Bellicum Pharmaceuticals, Inc.
    Full Title: A Phase I Study of Safety, Pharmacokinetics and Efficacy of Donor BPX-501 Cells and AP1903 Infusion for Children with Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic...
    Medical condition: recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10018849 Haematological disorders NEC HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004155-11 Sponsor Protocol Number: RN1004-0082 Start Date*: 2008-01-17
    Sponsor Name:Renovo Ltd
    Full Title: A double blind, placebo controlled trial to investigate the efficacy and safety of two concentrations of Juvidex in accelerating the healing of split thickness skin graft donor sites using differen...
    Medical condition: Acceleration of split thickness skin graft donor sites
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036892 Promotion of wound healing PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002077-35 Sponsor Protocol Number: EC-HEM-HGUGM-2016-01 Start Date*: 2017-05-05
    Sponsor Name:José Luís Díez Martín
    Full Title: CLINICAL TRIAL PHASE I / II, SINGLE-CENTER, HISTORICAL CONTROL, TO EVALUATE THE EFFECTIVENESS OF DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGN...
    Medical condition: High risk acute myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002879-34 Sponsor Protocol Number: PSCT16 Start Date*: 2013-03-05
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation
    Medical condition: Patients with aggressive hematological malignancies treated with allogeneic stem cell transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001514-34 Sponsor Protocol Number: ILNK15-01 Start Date*: 2012-04-03
    Sponsor Name:Leiden University Medical Center
    Full Title: Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study
    Medical condition: Children with high-risk and recurrent acute leukemia are eligible for allogeneic hematopoietic stem cell transplantation (HSCT). However, leukemia relapse and viral infections after HSCT remain mai...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10023685 LAK cell therapy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006862-27 Sponsor Protocol Number: CIK Start Date*: 2005-05-30
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: Infusion of Cytokine Induced Killer (CIK) cells in patients relapsing after allogeneic stem cell transplantation
    Medical condition: Patients with hematologic malignancies (excluding CML) with a hematologic or molecular relapse after allogeneic transplantation (at least 60 days should have elapsed since transplant).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002959-17 Sponsor Protocol Number: CR-BD-001 Start Date*: 2016-12-02
    Sponsor Name:Kiadis Pharma Netherlands B.V.
    Full Title: An exploratory, open-label study to evaluate the safety and feasibility of ATIR201, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic t...
    Medical condition: Patients with beta-thalassemia major who are eligible for a haploidentical HSCT
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10054661 Thalassemia major LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001335-31 Sponsor Protocol Number: virus-specific_CD8_T-cells_001 Start Date*: 2013-11-08
    Sponsor Name:Univerzita Karlova v Praze, 2. lékařská fakulta
    Full Title: Adoptive transfer of CMV specific CD8+ T-cells to treat CMV infection after transplantation
    Medical condition: chronic CMV infection after allogeneic hematopoietic stem cell transplantation in children, refractory to conventional antiviral treatment
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:09:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA